This page contains exclusive content for the member of the following sections: TTS, TID. Log in to view.
Presenter: Deborah, Marriott, Sydney, Australia
IFI in the era of antifungal prophylaxis’ implies a uniform implementation of antifungal prophylaxis in solid organ transplant recipients. However there is considerable heterogeneity in practice based on a number of factors including:
Antifungal prophylaxis choices include:-
The choice of strategy will have a significant impact of the nature and type of IFI that occurs. The timely use of diagnostic techniques such as Aspergillus PCR and the detection of galactomannan allows the implementation of targeted pre-emptive therapy and therefore reduces overall antifungal exposure. However the utility of biomarkers for screening has yet to be confirmed in the solid organ transplant setting.
Widespread implementation of antifungal prophylaxis comes at a price. Drug interactions, medication toxicity, financial cost and the emergence of resistant strains of yeast and moulds need to be weighed against the potential reduction in IFI. If azole antifungal therapy is administered there is general agreement that therapeutic drug monitoring is an important component of optimal patient management and should be available in real time to have an impact on dosing decision making.
By viewing the material on this site you understand and accept that: